Inozyme Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Inozyme Pharma's estimated annual revenue is currently $9.8M per year.
- Inozyme Pharma's estimated revenue per employee is $157,500
- Inozyme Pharma's total funding is $150.1M.
- Inozyme Pharma's current valuation is $157.4M. (January 2022)
Employee Data
- Inozyme Pharma has 62 Employees.
- Inozyme Pharma grew their employee count by -7% last year.
Inozyme Pharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder | Reveal Email/Phone |
2 | CEO and Chairman | Reveal Email/Phone |
3 | SVP HCP and Patient Engagement | Reveal Email/Phone |
4 | VP Clinical Operations | Reveal Email/Phone |
5 | VP, Quality & Compliance | Reveal Email/Phone |
6 | VP, Toxicology | Reveal Email/Phone |
7 | Head FP&A | Reveal Email/Phone |
8 | SVP Human Resources | Reveal Email/Phone |
9 | VP Worldwide Clinical Operations & Site Strategy | Reveal Email/Phone |
10 | Sr Director / Manufacturing and Process Development | Reveal Email/Phone |
Inozyme Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $50.8M | 328 | 3% | N/A | N/A |
What Is Inozyme Pharma?
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
keywords:N/A
$150.1M
Total Funding
62
Number of Employees
$9.8M
Revenue (est)
-7%
Employee Growth %
$157.4M
Valuation
N/A
Accelerator
Inozyme Pharma News
Thinking about buying stock in Obseva, Aterian, Inozyme Pharma, Aemetis, or Redbox? InvestorsObserver (PRNewsfoto/InvestorsObserver)...
Shares of Inozyme Pharma surged 17% on Thursday after SEC filings indicated stock purchases by company executives and a director.
Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment...
“Genomenon’s AI-driven data has the potential to greatly increase our collective understanding of ENPP1 Deficiency.” – Axel Bolte, Inozyme Pharma ANN ARBOR, Mich. (PRWEB) November 11, 2021 Genomenon, Inc.®, an AI-driven genomics company, announced a partnership with Inozyme Pharma to make crit ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 62 | 7% | $8.3M |
#2 | $7.2M | 62 | 27% | $2M |
#3 | $7.8M | 62 | 13% | $18M |
#4 | $7M | 62 | 27% | $62M |
#5 | $12.6M | 62 | -22% | $169M |